Exploring USFDA‐Approved Imidazole‐Based Small Molecules in Drug Discovery: A Mini Perspective
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202403020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Sonali Gupta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Division, Department of Pharmaceutical Sciences, Gurukul Kangri (Deemed to be University), Haridwar, India. Hauptthemen laut MEDLINE: Imidazoles, Drug Discovery, Small Molecule Libraries, Drug Approval. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 137 Literaturangaben.
Abstract (Originalsprache)
In the present work, we have explored the importance of the imidazole ring and its importance in drug discovery, citing the key approvals in the present decade (2013–2024). The pharmacological attribution for the approved drugs revealed that out of 20 approved drugs, 45% of the approvals were made as anti‐infectives, followed by approvals under the category of genetic and metabolic disorders, sexual endocrine disorders, anticancer, and to treat blood pressure, gastrointestinal disorders, and neurological conditions. Most approved drugs were dispensed through solid dosage forms (13) and thus had predominantly oral routes beside others. The metabolism pattern revealed that the drugs undergo metabolism via the involvement of multiple enzymes, where CYP3A4 and CYP3A5 were the core enzymes. The excretion pattern of these drugs revealed that the drugs are majorly excreted via the fecal route. The chemical analysis showed that pyrrolidine/pyrrole was the major heterocycle in the approved drugs, followed by the indole ring in the hybridization. Considering the substitution pattern, most drugs possessed amide, amines, and fluoro group as the functional substitution with the 2,4‐substitution pattern seen in most approved drugs. Besides this, the three approved drugs were found to possess chiral centers and exhibit chirality. The article also expanded to cover the synthetic routes and metabolic routes for this versatile ring system and case studies for its utility to serve as bioisostere in drug discovery. Furthermore, this article also presents the receptor–ligand interactions of imidazole‐based drugs with various target receptors. The present article is, therefore, put forth to assist medicinal chemists and chemists working in drug discovery of this versatile ring system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Chemistry Division, Department of Pharmaceutical Sciences, Gurukul Kangri (Deemed to be University), Haridwar, India.
- Department of Chemistry, Gurukul Kangri (Deemed to be University), Haridwar, India.
- Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
- Department of Microbiology, Central University of Punjab, Bathinda, Punjab, India.
- Department of Microbiology, Graphic Era (Deemed to be University), Dehradun, India.
- Centre of Research Impact and Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
ORCID-Profile: Kapil Kumar Goel, Bhupinder Kumar
Zitieren
APA
Gupta, S., Babu, M. A., Kumar, R., Singh, T. G., Goel, A., Rastogi, S., Sharma, P., Tyagi, Y., Goel, K. K., & Kumar, B. (2025). Exploring USFDA‐Approved Imidazole‐Based Small Molecules in Drug Discovery: A Mini Perspective. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202403020
Vancouver
Gupta S, Babu MA, Kumar R, Singh TG, Goel A, Rastogi S, et al. Exploring USFDA‐Approved Imidazole‐Based Small Molecules in Drug Discovery: A Mini Perspective. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202403020
BibTeX
@article{Gupta2025,
author = {Gupta, Sonali and Babu, M Arockia and Kumar, Roshan and Singh, Thakur Gurjeet and Goel, Anjali and Rastogi, Sameer and Sharma, Pankaj and Tyagi, Yogita and Goel, Kapil Kumar and Kumar, Bhupinder},
title = {Exploring USFDA‐Approved Imidazole‐Based Small Molecules in Drug Discovery: A Mini Perspective},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202403020}
}
EUVIMED